Clinical Trial Update: Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib [Phase 2]

View source ↗

Summary

Phase 2 trial investigating atezolizumab and bevacizumab in EGFR-mutant non-small cell lung cancer after progression on osimertinib; study terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Duke University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-12-26